Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 1374

The overall response rate in the trial population was 40% (95% CI 29%-51%). Median duration of response was 11.1 months (95% CI 6.9-not evaluable), with nearly two-thirds of patients having a duration of response of at least 6 months.

The FDA approved amivantamab-vmjw (Rybrevant) on Friday as the first treatment for patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.

Amivantamab is a bispecific antibody that targets EGFR and mesenchymal-epithelial transition factor pathways. EGFR exon 20 insertion mutations occur in approximately 2% to 3% of NSCLC patients, and are associated with rapid cell growth.

“Advances in precision oncology continue to facilitate drug development, allowing diseases like lung cancer to be subset into biomarker-defined populations appropriate for targeted therapies,” said Julia Beaver, MD, chief of medical oncology in the FDA’s Oncology Center of Excellence, in a statement. “With today’s approval, for the first time, patients with non-small cell lung cancer with EGFR exon 20 insertion mutations will have a targeted treatment option.”

Continue reading “FDA OKs Bispecific Antibody for Rare Lung Cancer Subtype” | >

Ageing is an incredibly complicated process, so much so that we do not yet understand exactly how complicated it is. It is in fact so complicated, that it could actually be incredibly simple. Confused? Well, imagine if you were a structural engineer who was trying to understand why a building collapsed. From an initial inspection of the rubble, it may be extremely difficult to work out exactly what went wrong. Was the building made from inferior materials? Was it built incorrectly? Was its destruction deliberate? Did it just fall apart due to age? All of these are possible, but what was the true cause for its destruction? Well, that is the same mystery we are trying to solve in longevity research. We can see the damage that is caused by ageing, but what is the cause? Is it a general accumulation of damage, or are there single points of failure which have knock on effects that affect the entire body? A cascade failure if you will.

Of the many different changes that occur during the ageing process, one of the most well-known and understood is the decreased capacity for our body to produced chemical energy, which has a knock-on effect throughout the body. This results in a general decrease in our ability to carry out cellular functions and will therefore effective everything from muscle strength to DNA replication and repair. This decrease in energy output has been linked to defects in our mitochondria, but in addition to these physical defects that occur in these small organisms, we now know that they also suffer a decreased capacity to carry out their function due to lacking a critical coenzyme called Nicotinamide adenine dinucleotide (NAD). Anyone who has taken a high school level biology class will probably recognise this enzyme as part of the electron transport chain in respiration.

Read more | >

“Deep in the forests of Germany, nestled neatly into the hollowed-out shells of acorns, live a smattering of ants who have stumbled upon a fountain of youth. They are born workers, but do not do much work. Their days are spent lollygagging about the nest, where their siblings shower them with gifts of food. They seem to elude the ravages of old age, retaining a durably adolescent physique, their outer shells soft and their hue distinctively tawny. Their scent, too, seems to shift, wafting out an alluring perfume that endears them to others. While their sisters, who have nearly identical genomes, perish within months of being born, these death-defying insects live on for years and years and years,” Katherine J. Wu writes.

A parasite gives its hosts the appearance of youth, and an unmatched social power in the colony.

Read more | >

Artificial intelligence (AI) is able to recognize the biological activity of natural products in a targeted manner, as researchers at ETH Zurich have demonstrated. Moreover, AI helps to find molecules that have the same effect as a natural substance but are easier to manufacture. This opens up huge possibilities for drug discovery, which also has potential to rewrite the rulebook for pharmaceutical research.

Nature has a vast store of medicinal substances. “Over 50 percent of all drugs today are inspired by nature,” says Gisbert Schneider, Professor of Computer-Assisted Drug Design at ETH Zurich. Nevertheless, he is convinced that we have tapped only a fraction of the potential of natural products. Together with his team, he has successfully demonstrated how artificial intelligence (AI) methods can be used in a targeted manner to find new pharmaceutical applications for natural products. Furthermore, AI methods are capable of helping to find alternatives to these compounds that have the same effect but are much easier and therefore cheaper to manufacture.

And so the ETH researchers are paving the way for an important medical advance: we currently have only about 4000 basically different medicines in total. In contrast, estimates of the number of human proteins reach up to 400000, each of which could be a target for a drug. There are good reasons for Schneider’s focus on nature in the search for new pharmaceutical agents. “Most natural products are by definition potential active ingredients that have been selected via evolutionary mechanisms,” he says.

Read more | >

They found that insulin sensitivity can be restored within days of reducing excess production of the neurotransmitter GABA in the liver and that long-term treatment may lead to decreased appetite and weight loss.

New research suggests that reducing the production of a neurotransmitter in the liver could help normalize blood sugar and treat type 2 diabetes.

Read more | >

Zoledronate is a biophosphonate, a drug used to strengthen bones and reduce the risk of osteoporosis-related bone fractures. It is well-absorbed into the bones, so it only needs to be administered through infusion once a year.

A 2010 study had found that people who were given zoledronate after experiencing hip fractures showed slightly reduced all-cause mortality compared to a control group. Patients who took the drug were at significantly lower risk for heart arrhythmias and pneumonia.

As this is a drug that is already being given to people, the choice to go back to genetically modified fruit flies, a much simpler model of aging, may seem counterintuitive. The team chose to test these insects for two principal reasons. The first is that Drosophila flies are a common subject of studies on basic aging pathways, which the researchers wished to explore. The second is simpler: Drosophila flies lack bones, making the bone-affecting properties of zoledronate irrelevant to the study.

Read more | >

Evidence suggests that what happens in one generation—diet, toxin exposure, trauma, fear—can have lasting effects on future generations. Scientists believe these effects result from epigenetic changes that occur in response to the environment and turn genes on or off without altering the genome or DNA sequence.

But how these changes are passed down through generations has not been understood, in part, because scientists have not had a simple way to study the phenomenon. A new study by researchers at the University of Maryland provides a potential tool for unraveling the mystery of how experiences can cause inheritable changes to an animal’s biology. By mating nematode worms, they produced permanent epigenetic changes that lasted for more than 300 generations. The research was published on July 9, 2021, in the journal Nature Communications.

“There’s a lot of interest in heritable epigenetics,” said Antony Jose, associate professor of cell biology and molecular genetics at UMD and senior author of the study. “But getting clear answers is difficult. For instance, if I’m on some diet today, how does that affect my children and grandchildren and so on? No one knows, because so many different variables are involved. But we’ve found this very simple method, through mating, to turn off a for multiple generations. And that gives us a huge opportunity to study how these stable epigenetic changes occur.”

Read more | >

The Retrobiome, Cancer, And Aging — Roswell Park Comprehensive Cancer CtrThe Retrobiome, Cancer, And Aging — Dr. Andrei Gudkov, PhD, DSci, Roswell Park Comprehensive Cancer Center, joins me on Progress, Potential, And Possibilities Cornell University College of Veterinary Medicine #Cancer #Vaika #Genome #DnaDamage #ImmunoSenescence #Pets #Dogs #Health #Lifespan #LifeExtension #Inflammaging #Longevity #Aging #Oncology

Dr Andrei Gudkov, PhD, DSci, is a preeminent cancer researcher who serves as Senior Vice President, Research Technology and Innovation, Chair of the Department of Cell Stress Biology, and a member of the senior leadership team for National Cancer Institute (NCI) Cancer Center Support Grant at Roswell Park Comprehensive Cancer Center (https://www.roswellpark.org/andrei-gudkov).

Dr. Gudkov is responsible for building on the basic and translational research strengths of the Cell Stress Biology program in DNA damage and repair, photodynamic therapy, thermal and hypoxic stress and immune modulation.

Continue reading “Dr. Andrei Gudkov, PhD — The Retrobiome, Cancer, And Aging — Roswell Park Comprehensive Cancer Ctr” | >

The researchers hypothesized that due to abnormal excitement of the Meynert basal ganglia, SB enters the brain and activates anticholinergic action to suppress abnormal acetylcholine secretion of acetylcholine-memory-related circuits centered on the Meynert basal ganglia, eliminating the flashbacks.

Fortunately, a group of Japanese researchers from the Sogo PTSD Institute, Medical Corporation Sogokai, Japan led by Dr. Masanobu Sogo appear to have made a breakthrough in PTSD treatment.

They have identified a drug called trihexyphenidyl, that can significantly reduce the flashbacks and nightmares experienced by patients with PTSD, according to a study published in Brain and Behavior.

Trihexyphenidyl is a central anticholinergic drug used to manage disorders like parkinsonism, and alleviate several side-effects induced by drugs acting on the central nervous system (CNS). It acts by blocking the activity of a neurotransmitter, acetylcholine, in the CNS. Interestingly, it has been available for therapeutic use for around 66 years.

Continue reading “Work Like a Dream: New Anticholinergic Drug Keeps PTSD Flashbacks and Nightmares Away” | >